The wide-moat firm's results were better than consensus, and we view the stock as slightly overvalued.
We view the company as slightly overvalued but don't expect any major changes to our fair value estimate.
Cost-saving plans and product launches should offset patent losses and drive growth.
We think that Albert Bourla will continue the wide-moat firm's current strategic focus.
A focus on unmet medical needs is helping pharma firms maintain their competitive advantage.
Innovation, clearing regulatory picture, corporate restructurings, and capital redeployment should continue for healthcare stocks in the fourth quarter.
Thanks to strong rare-disease drug data, we've edged up our fair value estimate on the drugmaker.
The market reaction to glyphosate's legal issues looks overdone.
Litigation concerns about glyphosate weedkillers are weighing on Bayer's shares, but we don't expect to make a significant change to our fair value estimate.
The company's entrenched products and developing pipeline are underappreciated.
Growth should moderate amid competition, but we view the stock as fairly valued today.
We don't expect any major changes to our fair value estimate after results were in line with expectations.
The negative news puts increased pressure on AbbVie's remaining pipeline to offset upcoming biosimilar pressures on its key drug Humira.
Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the second quarter.
We like Pfizer, Roche, Allergan, and Medtronic in this space.
The wide-moat firm is going through a paradigm shift, but it is well-positioned for growth.
The company's board is considering a sale or merger, which would maximize shareholder value and draw out the firm's full potential.
We expect the wide-moat drugmaker to take more share from Bristol, Roche, and AstraZeneca based on cross-trial comparisons that support Keytruda over competitive drugs.
We still see value in large-cap pharmaceutical and biotech firms despite Trump's plan to lower drug prices.
The pricing power of branded drugs in the U.S. still looks strong.
The two pharmaceutical giants are trading down due to the short-term miss, but their pipelines and pricing power look good.
The market doesn't fully appreciate the wide-moat drugmaker's long-term potential.
The wide-moat firm was buoyed by new drugs and expense controls, but we're not changing our fair value estimate.
We are increasing our fair value estimate after better that expected earnings but see the stock as fairly valued today.
New products in the pipeline can help the pharma firm continue to raise its payout.
Innovation, consolidation, and a mixed regulatory picture for healthcare stocks in the first- quarter.
4- and 5-star stocks are harder to come by in today's market, but a few values are still out there.
The firm’s exit from the process to buy Pfizer’s consumer healthcare business should relive dividend cut concerns.
Mixed phase 2 data for Rova-T has rocked the narrow-moat firm's stock price, but the data doesn't end the potential of the drug, only likely delays its pathway to approval.
The wide-moat drugmaker's cardiovascular drug, Praluent, which it has developed with Regeneron, enjoyed favorable results in a study.
Eli Lilly and Pfizer are well-positioned to bring out drugs with exceptional pricing power.
To achieve faster growth, the wide-moat pharmaceutical firm needs to improve its pipeline prospects.
We're raising our fair value estimate for the wide-moat firm after results ahead of both our expectations.
The overpayment to enter the increasingly competitive hemophilia market is relatively small compared with the overall size of wide-moat Sanofi.8445
Strong top-line Keytruda data reinforces the wide-moat pharma's first mover-advantage in the United States and will help launch the drug in Europe.
Innovation and redeployment of capital are factoring heavily in the sector.
We like the strong pipelines for both Roche and GlaxoSmithKline, and both are attractively priced today.
The market might be worried about the payout, but we think the headwinds facing the firm are manageable and see the dividend as stable.
Better standards align manager incentives with shareholder interests.
The wide-moat firm's strong lineup of next-generation drugs should counter the declines in externalized revenue.
The wide-moat drugmaker's third quarter was in line with our expectations, and we're not changing our fair value estimate.
We don't expect any major changes to our view after the wide-moat firm withdrew a drug application in Europe.
We don't plan to change our fair value estimate based on the results.
We saw minor outperformance from the wide-moat drugmaker, but we still view the stock as modestly undervalued today.
Third-quarter earnings were ahead of Street expectations, driven mostly by robust growth in the drug division.
Shares continue to look slightly overvalued after results that exceeded our expectations.
The undervalued pharmaceutical giant is cutting costs and has a strong pipeline, says Damien Conover.
The wide-moat drugmaker's plan to divest its consumer business will likely create only a minor level of value-creation for shareholders, at best.
Valuations in the healthcare sector in aggregate look fair, increasing the importance on stock selection where innovation and redeployment of capital weigh heavily.
With a secure wide moat and signs that sales growth will resume next year, investors should take a closer look at Pfizer shares today.